Valuation: Prostatype Genomics AB

Market Cap 70.51M 7.1M 6.34M 5.86M 5.31M 9.93M 674M 10.1M 27.92M 353M 26.66M 26.09M 1.11B P/E 2024
-0.38x
P/E 2025 -0.23x
Enterprise Value 66.75M 6.72M 6M 5.55M 5.03M 9.4M 638M 9.56M 26.43M 334M 25.23M 24.7M 1.05B EV / Sales 2024
327x
EV / Sales 2025 23.6x
Free-Float
84.84%
Yield 2024 *
-
Yield 2025 -
1 day+6.25%
1 week-1.92%
Current month+5.15%
1 month-15.00%
3 months-32.67%
6 months-87.06%
Current year-66.00%
1 week 0.09
Extreme 0.0938
0.1
1 month 0.08
Extreme 0.0788
0.12
Current year 0.08
Extreme 0.0788
2.28
1 year 0.08
Extreme 0.0788
2.28
3 years 0.08
Extreme 0.0788
365
5 years 0.08
Extreme 0.0788
12,000
10 years 0.08
Extreme 0.0788
18,400
Manager TitleAgeSince
Chief Executive Officer - 01/01/2017
Director of Finance/CFO - 31/10/2023
General Counsel - 01/03/2023
Director TitleAgeSince
Chairman - 01/01/2017
Director/Board Member - 01/01/2018
Director/Board Member 74 01/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.25%-1.92%-84.45%-99.94% 7.1M
-1.07%+1.20%+15.30%+35.48% 120B
+0.37%+2.22%+6.56%+94.67% 102B
+0.64%+2.67%+107.15%+907.86% 58.23B
+1.75%+2.27%-5.86%+82.21% 29.08B
-0.57%+2.93%+32.01%+99.17% 26.7B
-0.30%+3.46%+15.83%+66.20% 26.68B
-0.81%+0.45%+29.74%+391.13% 21.62B
-2.46%-5.71%-23.17%-7.12% 19.58B
-0.68%+2.72%+4.02%+82.89% 18.93B
Average +0.31%+0.63%+9.71%+165.25% 42.19B
Weighted average by Cap. -0.25%+1.64%+23.95%+197.69%

Financials

2024 2025
Net sales 199K 20.05K 17.9K 16.54K 14.99K 28.04K 1.9M 28.5K 78.79K 997K 75.23K 73.63K 3.14M 594K 59.84K 53.43K 49.36K 44.73K 83.69K 5.68M 85.07K 235K 2.98M 225K 220K 9.38M
Net income -41.05M -4.14M -3.69M -3.41M -3.09M -5.78M -393M -5.88M -16.25M -206M -15.52M -15.19M -648M -44.5M -4.48M -4M -3.7M -3.35M -6.27M -426M -6.37M -17.62M -223M -16.82M -16.47M -703M
Net Debt -9.35M -942K -841K -777K -704K -1.32M -89.44M -1.34M -3.7M -46.86M -3.54M -3.46M -148M -3.77M -380K -339K -313K -284K -531K -36.03M -540K -1.49M -18.88M -1.42M -1.39M -59.52M
Projected Income Statement - Annual - Prostatype Genomics AB
Logo Prostatype Genomics AB
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Employees
7
Date Price Change Volume
23/10/26 SEK 0.1020 +6.25% 2,586,003
22/10/26 SEK 0.0960 -6.80% 2,104,575
21/10/26 SEK 0.1030 +0.98% 1,853,618
20/10/26 SEK 0.1020 +2.00% 3,882,475
19/10/26 SEK 0.1000 -3.85% 7,710,108
  1. Stock Market
  2. Stocks
  3. PROGEN Stock